We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Tools
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Integrated Diagnostics Holdings Plc | LSE:IDHC | London | Ordinary Share | JE00BLKGSR75 | ORD USD0.25 |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.011 | 3.34% | 0.34 | 67,277 | 16:35:25 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 0.34 | 0.349 | 0.349 | 0.325 | 0.325 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Medical Laboratories | EGP 3.61B | EGP 541.11M | EGP 0.9019 | 0.39 | 210M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 17:04:59 | O | 65 | 0.34 | USD |
| Date | Time | Source | Headline |
|---|---|---|---|
| 16/11/2023 | 17:53 | ALNC |  EARNINGS AND TRADING: Integrated Diagnostics returns to profit |
| 16/11/2023 | 07:00 | UKREG | Integrated Diagnostics Holdings PLC 3rd Quarter Results |
| 25/10/2023 | 19:19 | ALNC | IN BRIEF: Integrated Diagnostics CEO buys 2.0m shares |
| 25/10/2023 | 06:00 | UKREG | Integrated Diagnostics Holdings PLC IDH CEO increases stake in the Company |
| 17/10/2023 | 13:26 | ALNC | IN BRIEF: Integrated Diagnostics CEO buys 1.1 million more shares |
| 17/10/2023 | 12:56 | UKREG | Integrated Diagnostics Holdings PLC Director/PDMR Shareholding |
| 16/10/2023 | 14:00 | ALNC | DIRECTOR DEALINGS: Schroders CFO buys GBP300,000 in shares |
| 16/10/2023 | 11:26 | UKREG | Integrated Diagnostics Holdings PLC Director/PDMR Shareholding |
| 13/10/2023 | 13:02 | UKREG | Integrated Diagnostics Holdings PLC Director/PDMR Shareholding |
| 12/10/2023 | 09:33 | UKREG | Integrated Diagnostics Holdings PLC Director/PDMR Shareholding |
Integrated Diagnostics (IDHC) Share Charts1 Year Integrated Diagnostics Chart |
|
1 Month Integrated Diagnostics Chart |
Intraday Integrated Diagnostics Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 23/10/2023 | 17:33 | Integrated Diagnostics | 65 |
| 19/8/2018 | 19:55 | Integrated Diagnostics (IDHC) One to Watch on Monday | - |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 2023-11-28 17:04:59 | 0.34 | 65 | 0.00 | O |
| 2023-11-28 16:54:12 | 0.33 | 2,260 | 0.00 | O |
| 2023-11-28 16:45:53 | 0.34 | 5,975 | 0.00 | O |
| 2023-11-28 16:35:25 | 0.34 | 5,142 | 0.00 | UT |
| 2023-11-28 16:28:14 | 0.35 | 3,797 | 0.00 | AT |
| Top Posts |
|---|
Posted at 28/11/2023 08:20 by Integrated Diagnostics Daily Update Integrated Diagnostics Holdings Plc is listed in the Medical Laboratories sector of the London Stock Exchange with ticker IDHC. The last closing price for Integrated Diagnostics was US$0.33.Integrated Diagnostics currently has 600,000,000 shares in issue. The market capitalisation of Integrated Diagnostics is £210,000,000. Integrated Diagnostics has a price to earnings ratio (PE ratio) of 0.39. This morning IDHC shares opened at US$0.33 |
Posted at 06/12/2022 14:41 by brucie5 Finally - (and then I'll stop!) I notice that IDHC was included in Mark Simpson's 40 stock folio for income investing, back on October 26. Important to stress it's a highly diversified folio, so can afford some geographically specific headwinds - no doubt the case with IDHC.He used this screen to generate the folio: Market Cap > £150m. TTM Earnings Yield, Rank in Market > 60% TTM Dividend Yield, Rank in Industry Group > 60% 1-Year Rolling Dividend Yield, Rank in Industry Group > 60% Net Gearing, including Pension < 50% This portfolio is forecast to yield 7.2%, and 17 of the constituents have bought back shares within the last month. This is a very reasonable income from a (hopefully) well-protected portfolio. Note: Though yielding above average for his folio, IDHC did not satisfy this last bit about director buy-backs, though as stated in previous posts, the CEO has a very high level of share ownership already! |
Posted at 06/12/2022 13:13 by brucie5 REWARDSTrading at 75.8% below our estimate of its fair value Earnings are forecast to grow 21.67% per year Trading at good value compared to peers and industry Analysts in good agreement that stock price will rise by 30.3% RISK ANALYSIS Dividend of 12.97% is not well covered by earnings or cash flows High level of non-cash earnings Profit margins (16.8%) are lower than last year (27.8%) |
Posted at 06/12/2022 13:09 by brucie5 Hmm. Large buy reported here: wonder if it's the boss' investment proxy hoovering up off the floor again. She owns c. 26% of the company, I believe.06-Dec-22 12:45:55 0.686 300,000 Buy* 0.672 0.70 205.80k This link is quite interesting in showing who the buyers/sellers have been over last months. |
Posted at 05/12/2022 11:10 by brucie5 Noone passed comment on these. Thorpematt, do you still hold?Business on the ground appears to be doing well, though depreciation of the EGP. 3(rd) Quarter Results Thursday, 17 November 2022 Integrated Diagnostics Holdings Plc reports sustained growth in non-Covid offering showcasing the fundamental strength and potential of the business (Cairo and London) - Integrated Diagnostics Holdings ("IDH," "the Group," or "the Company"), a leading consumer healthcare company with operations in Egypt, Jordan, Sudan and Nigeria, released today its reviewed financial statements and operational performance for the nine-month period ended 30 September 2022, reporting revenue (compliant with IFRS) of EGP 2.8 billion. In line with the trend seen earlier in the year, IDH's conventional business (which includes IDH's full service roster excluding Covid-19-related tests) continued to showcase its underlying strength and potential, delivering a solid 14% year-on-year expansion, partially offsetting the expected decline in Covid-19-related(1) revenues for the nine-month period. Growth at IDH's conventional business (which made up 76% of total revenues) was supported by a solid 7% increase in test volumes, testament to the robust underlying demand for the Company's conventional test portfolio. Likewise, on a quarterly basis, conventional revenues expanded 17% year-on-year and 12% quarter-on-quarter in Q3 2022, making it the strongest three-month period performance ever recorded by the Group's conventional offering. Meanwhile, consolidated revenue for the third quarter stood at EGP 846 million, with the Group recording a net loss of EGP 36 million in Q3 2022. It is important to note that controlling for the losses resulting from transactions completed by the Company to secure the USD balance needed to fulfil its FY2021 dividend obligations to shareholders, the Group would have recorded a net profit of EGP 544 million in 9M 2022 and EGP 105 million in Q3 2022. |
Posted at 07/9/2022 10:49 by brucie5 I may have misread it but... |
Posted at 05/8/2022 11:00 by brucie5 I had to blink, but there it is. 3.5m shares bought by the (PCA of) the CEO.1. Details of PDMR / person closely associated with them ("PCA") a) Name Hena Holdings Ltd -------------------- 2. Reason for the notification -------------------- a) Position / status PCA of Dr Hend El Sherbini, Chief Executive Officer -------------------- b) Initial notification Initial Notification / amendment -------------------- 3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor -------------------- a) Name Integrated Diagnostics Holding plc -------------------- b) LEI 2138007JN9NUWKKTS790 -------------------- 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted -------------------- a) Description IDH Ordinary Shares of $0.25 each of the financial instrument JE00BLKGSR75 Identification Code -------------------- b) Nature of the Purchase of shares transaction -------------------- c) Price(s) and Price(s) per share Volume(s) volume(s) USD 0.9000 3,562,737 ---------- -------------------- d) Aggregated information Aggregated volume 3,562,737 Price USD 0.9000 per share |
Posted at 04/8/2022 16:41 by essential Some big Director buying and the price drops 5%? |
Posted at 27/7/2022 16:51 by brucie5 Interesting RNS. How worried should we be? Share price hasn't responded at all, so the company appears to have reassured."Since the recommendation of the final dividend by IDH's board of directors and the subsequent declaration of the dividend by IDH's shareholders, the macro-economic situation globally and in Egypt has changed significantly. As such, despite its financial rigour and planning outlined above, IDH has encountered significant difficulties in sourcing the required amounts of USD to exchange for EGP for the purposes of making the Dividend Payment. This is largely as a consequence of the deteriorating broader macro-economic situation, including inflationary pressures and other consequences arising from the conflict in Ukraine, which has led to a scarcity of USD available in the foreign exchange markets for conversion to EGP. 2. Payment in full of dividend to minority shareholders today Despite the above-mentioned challenges, IDH has sourced sufficient USD to cover the full Dividend Payment due to all shareholders with the exception of its two largest shareholders, Hena Holdings Ltd ("Hena Holdings") and Actis IDH Limited ("Actis"), which have both agreed to defer their entitlement as described in section 3 of this release. IDH will begin paying the Dividend Payment due to all Eligible Shareholders (excluding Hena Holdings and Actis) as it falls due today (27 July 2022). 3. Deferral of dividend entitlement by IDH's two largest shareholders In light of these aforementioned difficulties in the foreign exchange market, IDH's two largest shareholders, Hena Holdings and Actis (the "Deferring Shareholders"), have agreed with IDH to defer the payment of their pro rata share of the Dividend Payment (being USD 17.7 million for Hena Holdings and USD 14.6 million for Actis, respectively) from 27 July 2022 to 27 January 2023 (the "Hena/Actis Deferral"). It is IDH's intention to seek to repay the sums due to both Deferring Shareholders as soon as it is practicably able to source the required USD currency. At this time, the Company expects the repayment to take place within the coming two months." |
Posted at 28/4/2022 09:08 by tomps2 IDHC pitched in the latest episode of Sell It To The CityNeil Cooper pitches Integrated Diagnostic Holdings (IDHC) to leading fund managers, Andy Brough, Judith MacKenzie and Stephen English at 25m47s in the latest PIWORLD Sell It To The city. Watch the video here: www.piworld.co.uk/ed Or listen to the podcast here: piworld.podbean.com/ |
Posted at 21/4/2022 13:17 by brucie5 What no interest???"Profitability came in at an all-time high, with adjusted EBITDA 1 growing 116% year-on-year to record EGP 2,530 million, and net profit recording a 145% year-on-year increase to reach EGP 1,493 million in FY 2021. In the final quarter of the year, IDH reported revenue of EGP 1,458 million, 48% above the previous year's figure, and net profit of EGP 345 million, up 47% from the comparable three month period of 2020. It is important to note that information in relation to the Company's full year results has been extracted from our audited annual report. Meanwhile, disclosures and statements in respect of quarterly information are unaudited. In light of IDH's outstanding performance for the twelve months ended 31 December 2021, IDH's board of directors has recommended a dividend distribution of EGP 2.17 per share, or EGP 1.3 billion in aggregate, to shareholders (exact US dollar amount is subject to the exchange rate at the time of the upstreaming from the subsidiaries to the holding company). This represents a significant increase compared to a final dividend of US$ 29.1 million distributed for the previous financial year." |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
|
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions Support: +44 (0) 203 8794 460 | support@advfn.com |
| ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil |
| ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico |
| ADVFN France ADVFN US ADVFN Korea |
